Femasys Inc
NASDAQ:FEMY
Gross Margin
Femasys Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Femasys Inc
NASDAQ:FEMY
|
28.7m USD |
67%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
228B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
176.8B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
147.9B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
142B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.6B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
65.6B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.1B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
42.3B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
286.9B CNY |
64%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
36.4B USD |
42%
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Femasys Inc's most recent financial statements, the company has Gross Margin of 66.6%.
You don't have any saved screeners yet